INVOcell Enables Same-Sex Couple to Both Physically Participate in the Pregnancy and Birth of Their Child
MEDFORD, Mass., Oct. 31, 2018 /PRNewswire/ — INVO Bioscience, Inc. (OTC: IVOB), a medical device company granted FDA clearance for the first Intravaginal Culture System, INVOcell™, today announced a successful pregnancy where both partners of a same-sex couple were able to carry the baby in separate phases of the pregnancy – from the fertilization of the egg and development of the embryo to the birth of the child.
The couple’s story has been featured in numerous national and international media outlets, including:
For access to additional news articles, please visit INVOBioscience.com.
Katie Karloff, Chief Executive Officer of INVO Bioscience, said, “We are thrilled that our INVOcell technology was instrumental in achieving a safe and successful pregnancy. Enabling both partners to physically participate in the pregnancy is a wonderful benefit of INVOcell. We applaud Drs. Kathy and Kevin Doody of Effortless IVF and The Center for Assisted Reproduction of Dallas/Fort Worth, Texas for their compassion and creativity to help this loving couple achieve the family they so passionately desired. Kathy and Kevin have been great advocates for the efficacy of INVOcell and we greatly appreciate their confidence in our technology.”
INVOcell is a patented medical device used in the treatment of infertility that enables egg fertilization and early embryo development to take place in the woman’s body, in vivo. The INVO Solution allows women to incubate their own gametes, providing a psychological benefit while reducing the risk of wrong embryo transfer. As a lower cost option to traditional IVF, INVOcell expands access to patients who may otherwise cannot afford the traditional method or would prefer for a more natural, cultural, or religious appropriate choice.
With the INVO Procedure, the temperature, carbon dioxide (CO2) and oxygen (O2), and physiological pH stay stable throughout the incubation period. There is no interference in the vaginal incubation environment which occurs in incubators due to the opening and closing of the incubator doors as well as the cycling of the temperature (thermostat). The INVOcell Culture Device uses the body as a natural incubator making it possible for the INVOcell device to maintain proper pH of the culture medium using the human body temperature, and CO2 and O2 concentration throughout the incubation period. The use of the INVOcell Culture Device in the vaginal cavity is a more stable environment than an incubator for temperature, and CO2 and O2 stability during fertilization and early embryo development.
“INVO Bioscience is dedicated to increasing access to care and expanding affordable fertility treatment and patient care across the globe,” said Lori Kahler, VP of Global Operations, INVO Bioscience. “For many couples struggling with infertility, access to treatment is often not possible. Financial challenges, limited availability of specialized medical care, religious, social or cultural roadblocks can prevent hopeful parents from realizing their dream to have a baby. Our mission is to help realize these dreams.”
KEY FEATURES & BENEFITS
Provides a more natural and stable incubation environment in the woman’s own body.
Provides psychological benefits to patients by promoting greater involvement by couples.
Lowers the cost of fertility treatments by approximately 50%.
Increases geographic accessibility to more patients with equivalent safety and efficacy compared to traditional IVF.
About INVO Bioscience
We are a medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility. Our solution, the INVO Procedure, is a disruptive new technology. The INVO Procedure is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Our lead product, the INVOcell, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI). Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase availability of care. For more information, please visit https://invobioscience.com/.
- For Safety and Efficacy information: https://invobioscience.com/wp-content/uploads/2016/03/INVO_IFU_Instructions_for_use.pdf
- For current Clinic Locations providing INVOcell: https://invobioscience.com/clinics/
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Kathleen Karloff, CEO
INVO Bioscience, Inc.
978-878-9505 ext. 504